This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry


Eliquis - More Promising than Existing Oral Anticoagulants II-20

Competitors Capitalize on Delay in Eliquis' Approval II-20

Do New Oral Anticoagulants Circumvent Issues with

Conventional Drugs? II-20

Hemostatic Agents for Reversing Action of New Oral Drugs - An

Area Demanding Active Research II-21



Injectable Anticoagulants- An Insight II-22

Heparin - The Back Bone of Injectable Anticoagulants II-22

Unfractionated Heparin II-22

Advantages and Alternatives II-23

Limitations II-23

Low Molecular Weight Heparins II-23

Indications II-24

Advantages II-24

Contraindications II-25

Side Effects II-25

Caution II-25

Costs II-25

Impediments II-25

A Focus on Select Heparin Based Injectables II-26

Lovenox/Clexane (enoxaparin) II-26

Approved Indications for Lovenox II-26

Advantages and Alternatives II-26

Table 2: World Lovenox Sales by Geographic Region

(2009-2011): Breakdown of Value Sales in US$ Million for

Western Europe, US, Emerging Markets and Others (includes

corresponding Graph/Chart) II-27

Fragmin (dalteparin sodium) II-27

Approved Indications for Fragmin Use II-28

Contraindications II-28

Precautions II-29

Fraxiparine (nadroparin) II-29

Innohep (tinzaparin) II-29

Contraindications II-30

Side Effects II-30

Other Serious Adverse Events Associated with Innohep II-31

Precautions II-31

Normiflo (ardeparin) II-31

Clivarine (reviparin) II-32

Table 3: Summary of Available LMWHs II-32

A Comparison of FDA Approved Indications for Select Injectable

LMWHs - Lovenox, Innohep and Fragmin II-33

Non-Heparin Anticoagulant Injectables - An Overview II-33

Arixtra (fondaparinux) II-33

Contraindications II-34

Market and Market Participants II-34

Angiomax (bivalirudin) II-34

Advantages II-35

Contraindications II-35

Side Effects II-35

Argatroban/Novastan II-35

Side Effects II-36

Precautions II-36

Refludan (lepirudin) II-36

Orgaran (danaparoid Sodium) II-37

Contraindications II-37

Side Effects II-38

Caution II-38

Precaution II-38

A Comparative Analysis of Various Direct Thrombin Inhibitors II-38



A Comparative Study of Warfarin Against LMWHs II-39

A Comparative Study of LMWH Against UFH II-40

A Comparative Study of New Anticoagulants/ Anticoagulant

3 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,087.62 +49.65 0.28%
S&P 500 2,112.83 +3.91 0.19%
NASDAQ 5,069.7650 +9.5190 0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs